Central Nervous System
FDA grants clearance to Minoryx for Phase III trial of cALD therapy
The US Food and Drug Administration (FDA) has granted clearance to Minoryx Therapeutics to initiate a Phase III clinical trial…
Alzinova doses first patient in extension part of Phase Ib ALZ-101 trial
Alzinova has dosed the first patient in the extension part of its ongoing Phase Ib study of ALZ-101 to treat…
Alterity initiates new Phase II advanced MSA therapy trial
Alterity Therapeutics has started a new Phase II clinical trial of ATH434 for the treatment of Multiple System Atrophy (MSA),…
FDA greenlights Neuralink for human trials
The US Food and Drug Administration (FDA) has approved Neuralink for its first in-human study. In a Twitter announcement, the…
BIAL R&D doses first patient in ACTIVATE study of BIA 28-6156
BIAL R&D has dosed the first patient in its Phase II ACTIVATE study of BIA 28-6156 to treat patients with…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Cybin doses first healthy volunteers in Part C of CYB004 study
Cybin has dosed the first healthy volunteers in the ongoing Part C of Phase I study of CYB004 to treat…
First subjects in IBC’s Phase Ib trial receive IBC-Ab002
ImmunoBrain Checkpoint (IBC) has announced the dosing of the first two patients in a Phase Ib trial of IBC-Ab002 to…
First patient dosed in Inhibikase’s Phase II Parkinson’s disease trial
Inhibikase Therapeutics has dosed the first patient in a Phase II ‘201’ clinical trial of IkT-148009 for the treatment of…
Roche’s BTK inhibitor succeeds in a Phase II MS trial
Roche’s fenebrutinib achieved positive results in a Phase II clinical trial in patients with relapsing forms of multiple sclerosis (RMS),…
Coya Therapeutics reports positive data from small Alzheimer’s disease trial
Coya Therapeutics has announced positive data from a small trial in Alzheimer’s disease as the company looks to build out…